How to Help Your Patients Find Blujepa in Stock: A Provider's Guide

How to Help Your Patients Find Blujepa in Stock: A Provider's Guide

You've determined that Blujepa (Gepotidacin) is the right antibiotic for your patient. Now comes the challenge many clinicians face in 2026: actually getting the prescription filled. This guide provides a practical, step-by-step approach to helping your patients locate Blujepa and navigate the access barriers that currently exist.

Current Availability Landscape

As of February 2026, Blujepa is not in shortage per the FDA's Drug Shortages database. GSK continues manufacturing, and the drug is available through standard pharmaceutical distribution channels.

The issue is pharmacy-level stocking. Because Blujepa is:

• Less than one year on the market (approved March 2025)
• Brand-only with no generic alternative
• Priced at $400-$600 per UTI course
• Used for specific indications (not a high-volume everyday antibiotic)

...many retail pharmacies simply don't carry it. This creates a gap between your prescribing decision and your patient's ability to fill the prescription.

Why Patients Can't Find Blujepa

Understanding the barriers helps you address them proactively:

1. Low Retail Stocking

Major chains stock medications based on demand history. A new drug with limited prescribing volume won't appear on shelves automatically. Independent pharmacies and hospital outpatient pharmacies tend to be more responsive to new products.

2. Insurance Friction

Prior authorization requirements and step therapy mandates create delays. When a pharmacy receives a prescription that requires PA, they often tell the patient to "come back when it's approved" — adding days to the process.

3. Cost Shock

Patients who discover a $400-$600 price tag at the counter may abandon the prescription. Without advance counseling about costs and assistance programs, patients may leave untreated.

4. Pharmacist Unfamiliarity

Some pharmacists may not yet be familiar with Gepotidacin and may question the prescription or suggest switching to a more familiar antibiotic. Clear clinical rationale on the prescription helps.

What Providers Can Do: 5 Practical Steps

Step 1: Check Availability Before Prescribing

Use Medfinder for Providers to check which pharmacies in your patient's area have Blujepa in stock. This takes seconds and prevents the frustration of sending a prescription to a pharmacy that doesn't carry the drug.

If no nearby pharmacies have it, you can:

• Call a pharmacy to confirm they can order it and get an arrival estimate
• Prescribe to a mail-order pharmacy
• Choose a pharmacy near a hospital or academic center

Step 2: Initiate Prior Authorization Early

Don't wait until the pharmacy rejects the claim. If your patient's insurance typically requires PA for new brand-name drugs:

• Submit the PA request when you make the prescribing decision
• Include clinical rationale: culture results showing resistance, prior treatment failures, allergy history
• Request expedited review for active infections that need prompt treatment

Many EHR systems can initiate electronic PA directly. Some payers also accept peer-to-peer reviews for faster turnaround.

Step 3: Provide a Backup Plan

Give your patient a clear contingency plan: "If the pharmacy can't fill Blujepa within 24 hours, call our office and we'll prescribe an alternative." This ensures the patient doesn't go untreated while waiting.

Document your preferred alternative in the chart so any covering provider can act on it.

Step 4: Counsel on Costs and Assistance

Brief your patient — or have your medical assistant do so — on what to expect:

• Insurance copay may range from $30-$150 depending on formulary tier
• Without insurance, expect $400-$600 for a UTI course
• GSK For You patient assistance program may help uninsured or underinsured patients (gskforyou.com, 1-888-825-5249)
• Discount cards from sites like GoodRx may provide some savings on brand-name pricing

Refer patients to our guide on saving money on Blujepa for detailed information.

Step 5: Include Clinical Rationale on the Prescription

When sending the e-prescription, include a note explaining why Blujepa was chosen. For example:

• "Culture-confirmed ESBL E. coli UTI; resistant to TMP-SMX, Nitrofurantoin CI due to CrCl"
• "Recurrent UTI with documented fluoroquinolone resistance; Gepotidacin appropriate per susceptibility"

This helps the pharmacist understand the clinical context and reduces callbacks questioning the prescription.

Alternative Agents When Blujepa Isn't Accessible

If Blujepa truly cannot be obtained in a clinically acceptable timeframe, established alternatives include:

• Nitrofurantoin (Macrobid): 100 mg BID x 5 days for uUTI — $10-$30 generic, widely available
• TMP-SMX (Bactrim DS): 1 tablet BID x 3 days for uUTI — $5-$20 generic (check local resistance rates)
• Fosfomycin (Monurol): 3g single dose for uUTI — $40-$80, good for resistant organisms
• Ceftriaxone: 500 mg IM single dose for gonorrhea — standard of care, $10-$50

For a patient-facing comparison, direct patients to our alternatives to Blujepa guide.

Workflow Tips for Your Practice

Create a Blujepa Protocol

Develop a simple protocol for your practice:

1. Check availability on Medfinder before prescribing
2. Submit PA simultaneously with the prescription
3. Provide patient with written backup plan and cost information
4. Schedule a follow-up check (phone or portal message) at 48 hours to confirm the prescription was filled

Educate Your Staff

Front desk and nursing staff should know:

• Blujepa is a new antibiotic — patients may call back saying the pharmacy doesn't have it
• The standard response: check Medfinder, offer to transfer the prescription, or escalate to the prescriber for an alternative
• GSK patient assistance information for cost-related callbacks

Track Outcomes

As you prescribe Blujepa more frequently, note which pharmacies successfully fill it. Over time, you'll build a mental (or actual) list of reliable pharmacy partners for this medication.

Final Thoughts

Blujepa is a clinically significant addition to the antimicrobial armamentarium, particularly for resistant UTIs and as an oral gonorrhea treatment option. The current access challenges are temporary and market-driven, not supply-driven.

By proactively checking availability with Medfinder for Providers, initiating insurance authorizations early, and equipping patients with backup plans, you can bridge the gap between prescribing Blujepa and your patient actually taking it.

For the patient perspective on finding this medication, share our guide: How to find Blujepa in stock near you.